The Role of Ceramide in Diabetic Retinopathy
The Role of Ceramide in Diabetic Retinopathy
批准号:
6931078
负责人:
MARK KESTER
金额:
$14.85万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-08-01 至 2007-07-31
关键词:
RNA interferencebiological signal transductioncaveolinscell deathceramidesdiabetes mellitusdiabetic retinopathyenzyme activitygenetically modified animalsinsulin receptorinsulin sensitivity /resistancelaboratory mouselaboratory ratlipid metabolismmembrane structuremolecular pathologyneuronspalmitatespathologic processposttranslational modificationsprotein kinaseprotein structure functionretinasecond messengerstransferase
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Diabetic retinopathy is characterized by altered vascular permeability and angiogenesis, as well as impaired insulin signaling and resulting apoptosis in retinal neurons. The project is based upon a paradigm shifting postulate suggesting that the underlying abnormality in diabetes is the inappropriate metabolism of palmitate into bioactive ceramide in peripheral non-adipose tissues, including the retina. A corollary to this postulate is that insulin-resistance is a consequence of augmented de novo ceramide synthesis, leading to disruption of insulin-dependent AKT signaling. The overall hypothesis of the present proposal is that altered ceramide metabolism in diabetes leads to insulin receptor dysfunction within membrane microdomains (rafts). Our preliminary data suggest that C16-ceramide selectively accumulates in diabetic retinas, a possible result of palmitic acid-induced de novo synthesis. In addition, exogenous ceramide mimics diabetic-induced insulin resistance, as evidenced by decreased AKT activity and cell viability. We specifically hypothesize that ceramide accumulation within lipid microdomains leads to diminished insulin receptor signaling as a consequence of altered interactions with signaling elements or scaffold proteins. We will use sophisticated biochemicals, molecular and genetic models to demonstrate that altered ceramide metabolism contributes to reduced insulin signaling in the retina. These studies have the potential to identify ceramide accumulation as a target that can be therapeutically or molecularly manipulated.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ceramide Nanoliposomes in Combination with Focused Ultrasound for Treating Breast Cancer
-
批准号:9750255
-
项目类别:
-
资助金额:$18.32万
-
财政年份:2018
-
负责人:MARK KESTER
-
依托单位:
Combination of ceramide and immunotherapy in treatment of hepatocellular cancer
-
批准号:10206045
-
项目类别:
-
资助金额:$55.31万
-
财政年份:2017
-
负责人:MARK KESTER
-
依托单位:
Combination of ceramide and immunotherapy in treatment of hepatocellular cancer
-
批准号:9403358
-
项目类别:
-
资助金额:$53.12万
-
财政年份:2017
-
负责人:MARK KESTER
-
依托单位:
Novel Nanoparticle Therapy for Pancreatic Cancer
-
批准号:9020214
-
项目类别:
-
资助金额:$31.32万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Clinical Trial of Ceramide nanoLiposomes in AML
-
批准号:10160825
-
项目类别:
-
资助金额:$57.19万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Biostatistics Core
-
批准号:8589114
-
项目类别:
-
资助金额:$2.3万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Administrative Core
-
批准号:8589115
-
项目类别:
-
资助金额:$8.56万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Novel Nanoparticle Therapy for Pancreatic Cancer
-
批准号:8827284
-
项目类别:
-
资助金额:$31.32万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Targeting Ceramide Metabolism in AML
-
批准号:8554594
-
项目类别:
-
资助金额:$30.57万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Novel Nanoparticle Therapy for Pancreatic Cancer
-
批准号:8638905
-
项目类别:
-
资助金额:$30.39万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Novel Nanoparticle Therapy for Pancreatic Cancer
-
批准号:8435991
-
项目类别:
-
资助金额:$31.33万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Targeted Sphingolipid Metabolism for Treatment of AML
-
批准号:10160824
-
项目类别:
-
资助金额:$199.55万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Targeted Sphingolipid Metabolism for Treatment of AML
-
批准号:8552151
-
项目类别:
-
资助金额:$198.9万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Targeting Sphingosine Kinase in AML
-
批准号:8554596
-
项目类别:
-
资助金额:$22.07万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Targeted Sphingolipid Metabolism for Treatment of AML
-
批准号:8732613
-
项目类别:
-
资助金额:$192.93万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Targeting Acid Ceramidase in AML
-
批准号:8554595
-
项目类别:
-
资助金额:$32.75万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
Novel Nanoparticle Therapy for Pancreatic Cancer
-
批准号:9248264
-
项目类别:
-
资助金额:$31.31万
-
财政年份:2013
-
负责人:MARK KESTER
-
依托单位:
The Role of Glycosphingolipids in Diabetic Retinopathy
-
批准号:7903885
-
项目类别:
-
资助金额:$38.22万
-
财政年份:2009
-
负责人:MARK KESTER
-
依托单位:
The Role of Glycosphingolipids in Diabetic Retinopathy
-
批准号:8106211
-
项目类别:
-
资助金额:$36.68万
-
财政年份:2009
-
负责人:MARK KESTER
-
依托单位:
The Role of Glycosphingolipids in Diabetic Retinopathy
-
批准号:7732069
-
项目类别:
-
资助金额:$38.61万
-
财政年份:2009
-
负责人:MARK KESTER
-
依托单位:
海外基金